A PHASE 1 ASCENDING AND PARALLEL GROUP TRIAL TO ESTABLISH THE SAFETY, TOLERABILITY AND PHARMACOKINETICS PROFILE OF VOLOCIXIMAB (ALPHA 5 BETA 1 INTEGRIN ANTAGONIST) IN SUBJECTS WITH NEOVASCULAR AGE- RELATED MACULAR DEGENERATION: